NAC (N-Acetyl Cysteine) for Bipolar Disorder
Acetylated form of the amino acid cysteine and the rate-limiting precursor for glutathione, the body's principal antioxidant; used clinically as the antidote for paracetamol overdose and studied for respiratory and mental health.
The connection
Mood disorder involving episodes of depression and mania or hypomania. Requires professional management.
Also known as: NAC, N-Acetyl-L-Cysteine
NAC (N-Acetyl Cysteine) × Bipolar Disorder: at a glance
Every published result for this pair, extracted and audited.
NAC (N-Acetyl Cysteine) / Bipolar Disorder: publication years
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Publications (count) |
|---|---|
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
NAC (N-Acetyl Cysteine) × Bipolar Disorder: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysisPetrelli F, et al. · Urologic oncology · 2026PMID 40935764 ↗02The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trialsEghdami S, et al. · Frontiers in psychiatry · 2024PMID 39376972 ↗03The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysisSadowski M, et al. · Journal of cellular and molecular medicine · 2024PMID 39632267 ↗04Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatmentde Oliveira MVS, et al. · Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2023PMID 36749887 ↗05Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysisLlano-León M, et al. · PloS one · 2023PMID 37104271 ↗06Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake InhibitorsGautam M · Journal of clinical psychopharmacology · 2023PMID 37335203 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.